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While oral consumption has been considered as the main exposure route 
of bis (2-ethylhexyl) phthalate (DEHP) for general public, dermal and 
inhalation cannot be ignored as alternative ones especially for consumer 
products. However, there were very limited information on quantitative 
contribution of exposure and metabolic profiles via inhalation after using 
consumer products. The purposes of the present study are: 1) quantitation 
of inhaled amounts of DEHP after use of a spray-type of consumer product, 
and 2) suggestion of fractional urinary excretion amounts of key 
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metabolites of DEHP after inhalation exposure in humans. In order to do 
so, seven young male Korean volunteers were recruited for an inhalation 
experiment, where they were located at a closed office room before single 
exposure to deuterium-labelled DEHP (DEHP-d4) with a compressible 
spraying anti-fog solution of DEHP-d4 at 500 mg/kg. Personal air 
monitoring of DEHP-d4 at breathing-zone was made and total excreted 
urine samples for forty eight hours after exposure were collected to 
measure key metabolites of DEHP-d4. Most aerosols of DEHP-d4 was 
clear out in about five minutes, and its air concentration was 1.73 ± 0.42 
mg/m3 for the first five minutes. The total cumulative excreted amount of 
the metabolites was 0.8 ± 0.5, 1.6 ± 0.4 and 3.3 ± 0.9 μg for mono-(2-
ethyl-5-hydroxyhexyl) phthalate-d4 (MEHHP-d4), mono(2-ethyl-5-
oxohexyl) phthalate-d4 (MEOHP-d4) and mono-(2-ethyl-5-carboxypentyl) 
phthalate-d4 (5cxMEPP-d4), respectively. The estimated inhaled amounts 
were 70.8 ± 17.3 μg (AM ± SD) based on an exposure model using the air 
measurements. MEHHP-d4, MEOHP-d4 and 5cxMEPP-d4 were 
determined as key metabolites of DEHP in urine as in other studies for 
exposure through ingestion; however, the relative production of 
metabolites among the analytes and fractional urinary excretion (Fue) 
relative to absorbed dose were different: 1.54 ± 0.74 %, 3.26 ± 1.49 % and 
6.42 ± 3.42 % for MEHHP-d4, MEOHP-d4 and 5cxMEPP-d4, respectively, 
which was about 2~20 folds lower than those though ingestion of DEHP. 
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While personal exposure amounts after single spraying action appeared 
about 3% of total released amounts of DEHP, inhalational exposure 
contributed to internal dose of DEHP, it would increase in multiple actions 
of spraying or continuous exposure. The fractional urinary excretion of 
DEHP metabolites indicate relatively low metabolism through exposure 
via inhalation, and dose estimation from urinary metabolites of DEHP with 
oral Fue could underestimate actual exposure as in occupational places 
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Ⅰ. Introduction  
 
Phthalates are widely used as plasticizers in polyvinyl-chloride products 
such as personal care products, toys, building materials, textiles, food 
containers, cosmetics, medical devices and clothes (IARC, 2000; ATSDR, 
2002; Schettler, 2006; US EPA, 2007 and EU, 2008). Because phthalates are 
ubiquitous in our surroundings, they have been exposed general population 
and their metabolites were widely detected in human urine (Anderson et al., 
2011). Phthalates are classified as endocrine disruptors and bis (2-ethylhexyl) 
phthalate (DEHP) is the most well-known toxic chemical among phthalates. 
Moreover, DEHP has been reported as a probably human carcinogenic 
chemical by the United States Environmental Protection Agency (US EPA, 
2007) and the International Agency for Research on Cancer (IARC, 2000). 
However, there are no regulated the legal or guidance levels of chemical 
substances in personal care products. Personal care products contain a large 
number of various chemicals and they exposed general people as well as 
worker (Duty et al., 2005; Sathyanarayana et al., 2008; Just et al., 2010; 
Koniecki et al., 2011; Romero-Franco et al., 2011).  
Although the major exposure route of DEHP for the general population is 
generally known to be dietary uptake, recently, many studies argued the 
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various DEHP exposure sources of indoor environments need to be given 
more importance. Specifically, literature has said that phthalates exposure via 
inhalation and dermal contact could be as significant as ingestion in the 
general population (Bekö et al., 2013). If there is possibility of exposure to 
phthalates, especially to DEHP, via inhalation, it is difficult to determine the 
accurate exposure information such as floating amount in air, intake dose 
(inhalation amount), levels of retention, absorbed amount in human body and 
pattern and levels of excreted metabolites. Previous studies of 
pharmacokinetic models to DEHP exposure were mostly ingestion pathway. 
Although there are some exposed studies via intravenous injection by ordinary 
medical treatment (given an injection of medical solution), it can’t be known 
how many exposed actual DEHP dose, which was estimated using fractional 
urinary excretion (Fue) calculated by ingestion of DEHP. To date, previous 
studies that estimated the intake dose of DEHP using exposure biomarker 
such as mono(2-ethylhexyl) phthalate (MEHP), mono(2-ethyl-5-oxohexyl) 
phthalate (MEOHP), mono-(2-ethyl-5-hydroxyhexyl) phthalate (MEHHP) and 
mono-(2-ethyl-5-carboxypentyl) phthalate (5cxMEPP) in urine have used Fue 
calculated by ingestion of DEHP regardless of exposure route (Kohn et al., 
2000; Calafat et al., 2006; Marsee et al., 2006; Itoh et al., 2007; Guo et al., 
2011; Fong et al., 2014 and Cao et al., 2016). As we know, no study on DEHP 
exposure was conducted on humans or animals via inhalation for the 
development of fractional urinary excretion and absorption rate from air to the 
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human body. The studies on DEHP exposure via inhalation were only 
conducted for cytotoxicity, developmental toxicity and effect to target organ 
limited in-vivo and in-vitro studies (Merkle et al., 1988; Klimisch et al., 1922; 
Kurahashi et al., 2005 and Ma et al., 2006).  
In previous studies (Fong et al., 2014 and Cao et al., 2016), comparison of 
daily intake dose of DEHP estimated from the exposure model using 
environmental data and the dose-reconstruction with exposure biomarkers 
concentration in biological samples. The intake dose estimated from the 
biomarker should be higher than the one estimated from environmental 
monitoring on the assumption that biomonitoring is the reflected all exposure 
pathway (NRCNA, 2006), but not always in those studies. There were many 
uncertainty and we suggested the one that was to use Fue calculated by 
ingestion of DEHP because of no information about absorption factor 
depending on exposure route such as ingestion, inhalation and dermal contacts. 
The purposes of this study are: 1) Estimation of the intake dose with an 
exposure model after inhalation of sprayed DEHP solution to human and 2) 
suggestion on Fue calculated by inhalation of DEHP.  
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Ⅱ. Materials and methods 
 
1. Chemicals and reagents 
Bis[(±)-2-ethylhexy] Phthalate-3,4,5,6-d4 (DEHP-d4, >99 %) was purchased 
from C/D/N Isotopes Inc. (Canada) for measurement of concentration in air 
sample and di-n-Butyl phthalate-d4 (DnBP-d4 as internal standard was 
purchased from AccuStandard® (USA). For analysis of urinary excreted 
metabolites, we purchased mono(2-ethylhexyl) phthalate-d4 (MEHP-d4, 
>98 %) in C/D/N Isotopes Inc. (Canada); 13C4-mono(2-ethyl-5-oxohexyl) 
phthalate (13C4-MEOHP, >99 %), 
13C4-mono-(2-ethyl-5-hydroxyhexyl) 
phthalate (13C4-MEHHP, >99 %), 
13C4-mono-(2-ethyl-5-carboxypentyl) 
phthalate (13C4-5cx-MEPP, >99 %) and 
13C4-mono-n-butyl phthalate (
13C4-
MnBP, >99 %) in Cambridge Isotope Laboratories, Inc. (USA). We purchased 
acetonitrile, methanol, and water (HPLC grade) from J.T.Baker; formic acid 
(98+ %) from ACROS Ordanics; and ammonium acetate (≥97 %), β-
Glucuronidase (from Helix pomatia) and Sulfatase (from Helix pomatia) from 
Sigma-Aldrich (USA).  
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2. Subjects and exposure condition 
The present study was approved by the institutional Review Board of Seoul 
National University (No. 1408/002-006). We recruited seven subjects by 
posting on off- and on-line board at Seoul national university. All subjects 
participated in this study on their own volition. They have not any health 
problem (such as allergy, asthma and skin disease etc.) and are all male and 
Korean. Subjects were recommended to wear protective clothing and glove in 
exposure room because we wanted to only expose via inhalation pathway. 
Subjects were allowed free access to food, water and beverage and filled in 
the questionnaire for lifestyle and chart of living pattern during experiment 
period. 
Temperature and humidity of exposure room was 10.4 ± 0.2 °C (10.1 - 
10.8 °C) and 46 ± 4 % (40 - 49 %), respectively (AM ± SD (range)). Before 
subjects entered, the exposure room was naturally ventilated. When subjects 
entered the exposure room, all window and door was closed and indoor air 
was circulated by fan. Exposure solution was added standard chemical of 500 
mg in 30 mL mixture of anti-fog product and ethanol (16.7 mg/mL) and all 
sprayed using compressible spray. Subjects are exposed by single spraying for 




For finding proper air sampling time, we collected particulate matters (PMs) 
time-profile using Portable Aerosol Spectrometer 1.109 (Grimm Aerosol 
Technik, Ainring, Germany) and SidePak personal aerosol monitor (TSI, 
model AM510, data logging only PM1.0). Personal and area air sample were 
collected at breathing-zone and center of table (OSHA, 1994), which was 
placed in center sprayed exposure solution, respectively. Area air sample was 
collected at the following time points: 0, 5, 10, 15, 30 and 60 minutes after 
spraying. We collected air sampling at 1 L/min with an OVS-tenax sampling 
tube (Cat No. 226-56, SKC, USA) that contains 140 mg tenax resin and glass 
fiber filter in the front section and 70 mg tenax resin in the back-up section. 
Air sample were stored at -20 °C until analysis. 
All excreted urine samples were collected in screw-capped polypropylene 
bottles and excreted volume of urine was measured. Cumulative excreted 
amount of the metabolites was calculated to multiply measured concentration 
of the metabolites in urine using instrumental analysis by excreted volume of 
urine. Collected urine samples were stored at -80 °C until analysis. 
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4. Preparation and analysis of samples 
Preparation of air sample was referenced from OSHA method 104 (1994). 
Air samples were defrosted at room temperature for one hour before 
preparation. Air sample was divided up the front and the back-up sections in 4 
mL amber vial with screw-capped. Each air sample vial was added 4 mL of 
the desorbing solvent, toluene, capped and mixed well. Blank sample of 
laboratory and field wasn’t detected of DEHP-d4 and all air sample wasn’t 
observed breakthrough. Blank samples of laboratory and field weren’t 
detected of DEHP-d4. 
DEHP-d4 in air samples was analyzed by a Agilent 6890N gas 
chromatograph equipped with a Agilent 7683 automatic liquid sample coupled 
to a Agilent 5975N mass selective detector. Concentration of DEHP-d4 was 
quantitated using DnBP-d4 as internal standard. GC analysis was performed 
on a HP-5MS (30 m × 0.25 mm ID, 0.25 um film thickness, 5 % 
phenylmethyl silicone, Agilnt technologies, USA) with helium as carrier gas 
(1 mL/min). Gradient condition of oven temperature was applied; 0 - 1 min, 
60 °C; 1 - 9 min, 60 - 220 °C and 9 - 25 min, 220 - 300 °C and 25 - 28 min, 




Preparation of urine samples was referenced from Kato (2006) and Lee 
(2013). Urine samples were defrosted at room temperature for two hours. 980 
μL of urine was add 20 μL of internal standards (MnBP-d4 0.5 μg/mL), 100 
μL of ammonium acetate (1 M), 20 μL of enzyme mixture (β-glucuronidase 
926 unit/mL and sulfatase 926 unit/mL). Enzyme base buffer solution (1 M 
ammonium acetate) was adjusted pH 5.0. Urine samples incubated at 37 °C 
for two hours. After incubation, we added 2 mL 0.1 M formic acid to each 
sample. We extracted the DEHP metabolites in urine on solid phase extraction 
(SPE) manifold using Oasis HLB 60 mg/ 3 mL SPE cartridges (Waters Corp., 
Milford, MA) and compressed with 2 to 3 psi pressure. The cartridges were 
conditioned with 3 mL of methanol and 3 mL of water. The treated sample 
was loaded onto the SPE cartridge. The conical tubes contained samples were 
washed by 1 mL water and loaded in SPE cartridges. The cartridge was rinsed 
with 10 % methanol (3 mL), completely dried for two hours and extracted 
with 3 mL of methanol in new 15 mL conical tube. Extracted solution in 
conical tube was dried using nitrogen gas (99.999 %) purging. Empty conical 
tube was spiked 70 % methanol (100 μL) for reconstitution and mixed well. 
Reconstitution samples were centrifuged (10000 rpm, 10 min) and taken 80 
μL of supernatant liquid.  
The levels of DEHP-d4 metabolites were measured using liquid 
chromatography – tandem mass spectrometry with an AB Sciex 4000 tandem 
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mass spectrometer (Framingham, MA, USA) coupled to the Shimazu HPLC 
system (Kyoto, Japan). HPLC analysis was performed on a Shicheido 
CAPCELL PAK C18 ACR column (2.0 x 150 mm ID, 3 μm) and the column 
maintained at 35 °C in a thermostatic column oven. The mobile phase was 
0.1 % acetic acid in water (solvent A) and in acetonitrile (solvent B) with flow 
rate of 0.2 mL/min. Gradient condition was applied; 0.0 - 2.5 min, 10 % B; 
2.5 - 3.0 min, 10 - 30 % B; 3.0 - 5.0 min, 30 - 40 % B; 5.0 - 7.0 min, 40 % B; 
7.0 - 11.0 min, 40 - 55 % B; 11.0 - 12.0 min, 55 - 100 % B; 12.0 - 16.0 min, 
100 % B and 16.1 - 20.0 min, 10 % B. The MS/MS system was used in ESI-
mode. An injection volume of 5 μL was used and data acquisition was 
performed using Analyst 1.5.2 software (AB Sciex, USA).  
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5. Method validation and QA/QC 
The method validation of analytical methods was performed at three days 
because of confirming reliability to each method and was made into low and 
high concentration (LQ and HQ, 1 and 10 ng/mL in urine) spiked standard 
chemical working solution. The precision and accuracy ranges were 2.5 - 4.2 % 
and 93.8 - 103.3 %, respectively. 
We used experimenter urine for QA/QC because of not effected exposure to 
DEHP-d4. The QA/QC urine samples were prepared the same as validation 
and real samples and analyzed each batch. The precision and accuracy ranges 
were 9.7 – 17.2 % and 94.1 – 104.3 %, respectively. In this study, because 
results of MEHP-d4 weren’t statistical confidence, it excluded from data 
interpretation. All method validation and QA/QC results represent supplement 
information including air and urine data (Table S1 and S2).  
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6. Exposure model and fractional urinary excretion 
Estimated intake dose through external data in this case air monitoring data 
was calculated using exposure model (Eq. 1). Other exposure route was not 
considered because of the assumption that subjects were only exposed DEHP-
d4 via inhalation. 
   =   ×   ×    (Eq. 1) 
Parameters of Eq. 1 means that IDa (μg) is estimated intake dose (absorption 
amount) via inhalation using personal air sample; Ca (μg/m
3) is measured 
concentration of DEHP-d4 in air using personal air sample; IR (0.49 m
3/h) is 
inhalation rate of 20’s male at rest (KEFH, 2007) and ET (0.08 h, 5 min) is 
exposure time. 
The fractional urinary excretion (Fue) of the excreted amount of the 
metabolites relative to the DEHP-d4 was calculated by Eq. 2. It simply means 
that a molecular dose ratio of the metabolites related to the intake dose of 
DEHP-d4. 
   (%) =
   
  
×
   
   
× 100 (Eq. 2) 
Parameters of Eq. 2 means that Fue (%) is molecular fractional urinary 
excretion of DEHP-d4 and the metabolites measured in this study; Am (μg) is 
total cumulative excreted amount of the metabolite in urine and MWD 
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(μg/μmol) is molecular weight of DEHP-d4 and MWm (μg/μmol) is molecular 






The demographic characteristics for seven subjects are summarized in Table 
1. The subjects aged greater than 18 years, with a body mass index between 







Table 1. Demographic characteristics of seven subjects 
 










A 27 72 184 21.3 
B 25 80 183 23.9 
C 22 50 165 18.4 
D 19 69 165 25.3 
E 25 58 170 20.1 
F 20 71 176 22.9 
G 25 76 178 24.0 
Mean ± SD 23 ± 3 68 ± 10 174 ± 8 22.3 ± 2.5 
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2. Time-profile of particulate matters and concentration of DEHP-d4 in air 
Figure 1 illustrates the time-profile of PM1.0 and PM2.5 mass concentration in 
exposure room measured using Portable Aerosol Spectrometer (PAS). Five 
minutes before spraying (5 min), subjects entered the exposure room and sat. 
After two minutes of spraying (12 min), PMs concentration was the highest 
level. About seventy percent of PMs concentration was decreased after 
spraying for five minutes by adjusting background level (15 min). The trend 
of the time profile of PM1.0 using SidePak was similar to PAS results (data not 
shown). 
As shown in the Figure 1, single spraying of exposure solution was the major 
determinants for the amount of DEHP-d4 in air sample. Time-weighted 
average concentrations of DEHP-d4 in air calculated by area air sample were 
dropped with time (Figure 2). Therefore, exposure time was determined as 
five minutes to calculate the concentration of DEHP-d4 in air using personal 
air sample on the basis of time-profile of PMs and DEHP-d4 concentration of 
area air sample. 
Table 2 represents the DEHP-d4 concentration of air measured using personal 
and area air sample for five minutes after spraying of DEHP-d4 solution. The 
air concentration measured using personal and area air sample was 1.73 ± 








Figure 1. Time-profile of particulate matters concentration in air of exposure 









Figure 2. Time-weighted average concentration of DEHP-d4 in air after 
spraying of DEHP-d4 solution. Each data point represents the arithmetic mean 







Table 2. Air concentration of DEHP-d4 in personal and area air sample for the 
first five minutes after spraying 
Subject 
DEHP-d4 concentration 
in air (mg/m3) 








AM ± SD 1.73 ± 0.42 
Area air sample (n=2)  





3. Cumulative excreted amount in urine 
Cumulative urinary eliminated amounts were derived multiplying urinary 
volume by the concentration of each metabolite - MEHHP-d4, MEOHP-d4 and 
5cxMEPP-d4. For 48 hours after exposing, the arithmetic mean and the 
standard deviation were 0.8 ± 0.5, 1.6 ± 0.4 and 3.3 ± 0.9 μg (0.003 ± 0.002, 
0.005 ± 0.002 and 0.011 ± 0.003 μmol) for MEHHP-d4, MEOHP-d4 and 




4. Estimation of intake dose and fractional urinary excretion 
Table 3 shows that intake dose of DEHP-d4 via inhalation estimated by 
exposure model (Ep. 1), which is used air concentration calculated by air 
sampled at subjects’ breathing-zone. Estimated intake dose of DEHP-d4 was 
70.8 ± 17.3 μg (0.180 ± 0.044 μmol, AM ± SD). 
The fractional urinary excretion calculated by bio-sample in this study (Eq. 
2). Because the level of estimated intake dose of DEHP-d4 and cumulative 
excreted amount of the metabolites in urine differed from individual to 
individual, the fractional urinary excretion of the metabolites were different 
from each person. The range of MEHHP-d4, MEOHP-d4 and 5cxMEPP-d4 
were 0.56 – 2.70 %, 2.13 – 6.47 % and 3.79 – 13.9 %, respectively. 
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Cumulative excreted amount 
in urineb (μmol) 
Fractional urinary excretionc (Fue, %) 
MEHHP-d4 MEOHP-d4 5cxMEPP-d4 MEHHP-d4 MEOHP-d4 5cxMEPP-d4 
A 0.098 0.002 0.006 0.014 2.06 6.47 13.9 
B 0.164 0.001 0.004 0.010 0.56 2.59 6.18 
C 0.203 0.003 0.005 0.008 1.67 2.25 3.89 
D 0.204 0.002 0.006 0.011 0.77 3.00 5.50 
E 0.167 0.002 0.004 0.006 1.30 2.13 3.79 
F 0.185 0.003 0.005 0.011 1.72 2.95 5.79 
G 0.236 0.006 0.008 0.014 2.70 3.40 5.91 
Aver 0.180 0.003 0.005 0.011 1.54 3.26 6.42 
SD 0.044 0.002 0.002 0.003 0.74 1.49 3.42 
[Notes] a: calculated by Eq. 1; IDa = (DEHP-d4 concentration) × (inhalation rate) × (exposure time) / (molecular weight),  
b: sampled for 48 hr after exposure to DEHP-d4  and 
c: calculated by Eq. 2; Fue = (IDa /total cumulative excreted amount of 





We performed the first human study about DEHP exposure via inhalation to 
suggest fractional urinary excretion (Fue) of inhalation exposed to DEHP. 
Inhalation exposure route avoids first-pass effect, which was degradation of a 
chemical in the liver before it reaches the systemic circulation, unlike 
ingestion (Kwon et al., 2008 and Antosova et al., 2009). We expected that Fue 
of inhalation was higher than Fue of ingestion. However Fue of inhalation was 
about 2-to-20 times lower than previous studies exposed via ingestion. 
Nevertheless, Fue of present study should simply utilize to conduct exposure 
assessment even though it included many uncertainty such as unknowingness 
of true intake dose and assumptions.  
If DEHP mostly exposed via inhalation, to apply Fue of oral exposure may 
not calculate intake dose reflected to reality. Therefore, we recommend to use 
the Fue of inhalation exposed to DEHP instead of using Fue in certain cases. 
Fong (2014) was conducted the study that comparison of intake dose using 
exposure- and bio-model to PVC production workers who were mainly 
exposed to DEHP via inhalation. The result was shown that estimated intake 
dose using bio-model was lower than exposure model in some case. 
Representatively, it may not be proper using of Fue calculated by oral exposure 
of DEHP because biomonitoring is the reflected all exposure pathway 
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(NRCNA, 2006). The dose-reconstruction with exposure biomarkers 
concentration were conducted dividing total excreted molar amount of 
metabolites by Fue. To use of Fue calculated by oral exposure means that we 
should be possible to underestimate the intake dose of exposed DEHP via 
inhalation because of lower Fue of present study than others. 
In the present study, type of excreted metabolites was same with previous 
studies and the dominantly excreted metabolite in human urine was 
5cxMEPP-d4 followed by MEOHP-d4 and MEHHP-d4. The total cumulative 
excreted amount of 5cxMEPP-d4 was four times higher than MEHHP-d4. On 
the contrary, many biomonitoring studies including studies of artificial 
exposure to DEHP via ingestion and intravenous reported that the 
predominant metabolites were MEHHP or 5cxMEPP followed MEOHP and 
MEHP in order (Koch et al., 2004 , 2005 and 2011; Becker et al,. 2004 and 
2009; Boas et al., 2010; Anderson et al., 2011; Guo et al., 2011a and 2011b; 
Kasper-Sonnenberg et al., 2012; Kim et al., 2014 and Cao et al., 2016). 
Furthermore, the ratio of each metabolites was not similar with the literature 
value. However, the excreted pattern of the metabolites in Kessler et al. (2012) 
was not accord with many previous studied, although same exposure route 
(ingestion). These difference wasn’t clearly explained. Anderson et al. (2011) 
showed that three metabolite of DEHP had no statistically significant effects 
of gender and MEHHP and 5cxMEPP were detectable effects of exposure 
dose of DEHP. We supposed that the excreted pattern of DEHP metabolites 
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could be effected on many factors such as exposure route and concentration, 
sex and race etc. and need to further study. 
According to the results for time-profile of particulate matter data (Figure 
1), sprayed aerosol using the compressible spray was settled on surface (table 
and floor) of enclosed exposure room in five minutes. We supposed that 
sprayed DEHP-d4 droplets almost existed as particle phase in air and were 
exposed to the subjects in a short time (about 2 - 3 min) and it confirmed 
time-weighted average concentrations of DEHP-d4 in air calculated using area 
air sample were dropped with time as seen Figure 2.  
We investigated intake dose of inhaled DEHP-d4 and fractional urinary 
excretion of the metabolites at single spraying. We could find that inhalation 
exposure to DEHP was not higher than expected. These results needed to 
carefully use on exposure assessment of inhalation exposed to DEHP, because 
there were a lot of uncertainties and assumptions. Limitation of present study 
was only performed on 20’s Korean male. Therefore, further study demand to 
conduct study of exposure various condition such as sex, age and exposure 
duration, frequency, concentration and phase of DEHP. In conclusion, we 
recommend to utilize the Fue of inhalation exposed to DEHP instead of using 






We conducted human study of DEHP exposure via inhalation. When single 
spraying of DEHP, aerosols were mostly particle phase and settled down in 
five minutes. We calculated 70.8 μg of estimated intake dose using 
environmental monitoring data (IDa) and suggested fractional urinary 
excretion (Fue) of inhalation, which was about 2 - 20 times lower than Fue of 
ingestion. It means that dose estimation of DEHP with Fue of ingestion might 
underestimate the actual intake amount via inhalation. Therefore, we 
recommended that the dose-reconstruction with exposure biomarkers 
concentration in biological samples should use Fue of inhalation when was 
similar condition with present study. In conclusion, the Fue of present study 
should be utilizable as basic data to conduct exposure assessment of DEHP 
via inhalation when people mainly exposed to DEHP formed particulate 
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Ⅶ. Supplementary information 
 
Dose reconstruction from urinary biomarkers 
in a human panel exposed to bis (2-ethylhexyl) 
phthalate via inhalation 
 
Table S1. Intra and inter-day precision and accuracy of DEHP-d4 and their 
four metabolites for method validation (n=9) 
 
Table S2. Precision and accuracy of DEHP-d4 and their four metabolites for 







Table S1. Intra and inter-day precision and accuracy of DEHP-d4 and their 








Air DEHP-d4 100 4.1 4.0 98.5 
  200 3.2 3.5 103.2 
  1600 2.8 2.8 100.0 
Urine MEHP-d4 1 18.4 20.6 63.0 
  10 11.5 16.8 67.5 
 MEHHP-d4 1 3.7 4.1 98.8 
  10 2.9 3.2 99.7 
 MEOHP-d4 1 4.2 4.1 93.8 
  10 3.0 3.3 98.6 
 5cxMEPP-d4 1 3.1 3.1 101.7 






Table S2. Precision and accuracy of DEHP-d4 and their four metabolites for 
QA/QC during sample analysis 








Air DEHP-d4 10 200 8.7 97.1 
Urine MEHP-d4 30 1 28.9 76.1 
  30 10 27.4 80.9 
 MEHHP-d4 30 1 17.2 104.3 
  30 10 9.7 99.2 
 MEOHP-d4 30 1 10.6 94.1 
  30 10 9.8 101.8 
 5cxMEPP-d4 30 1 10.0 98.5 






요  바이 마커를 이용  DEHP  
인체 입 노출량 추  
 
울  보건 원 경보건 과 
   
 
 
일반 인구집단에  DEHP 주  식 료, 지 등  취가 
주요 노출경  알  있지만, DEHP가 함  생 용
품  사용 는 경우 입이나 부  통  노출이 일어난
다고 보고 고 있다. 그럼에도 불구 고 아직 지 DEHP에 
입 노출  평가   있는 연구는 이루어  있지 않다. 라  
본 연구  목  1) 노출모델  이용 여 DEHP 입 노출
량  추 고, 2) DEHP 입노출 시 소변  배출  산출
여, 이를 구강 취 노출  산출  타 헌  소변  배출
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 는 것이다. 본 연구는 국 인남  7명  상
 압축식 스 이를 이용 여 DEHP-d4 용액  분사 여 
입노출 시 고, 험자   반구에  채취  공  시료  
노출 후 48시간 동안 배출 는 모든 소변  채취 여 DEHP
 그 사산  분 다. 공   DEHP-d4  시간가
평균 농도는 1.73 ± 0.42 mg/m3 이었고, 노출 후 48시간 
동안 소변  통 여 배 는 사산   배출량  
MEHHP-d4 0.8 ± 0.5 ㎍, MEOHP-d4 1.6 ± 0.4 ㎍ 그리
고 5cxMEPP-d4 3.3 ± 0.9 ㎍ 이었다. 공  시료  농도를 
이용  노출모델  통 여 추  노출량  평균 70.8 ㎍ 이
었고, 이  소변  배출  사산  양  이용 여 산출  
소변  배출  계산 며 MEHHP-d4 1.54 ± 0.74 %, 
MEOHP-d4 3.26 ± 1.49 % 그리고 5cxMEPP-d4 4.62 ± 
3.42 % 이었다. 소변  사산  경우, 구강 취 노출 었
 타 연구에  배출  사산  종  동일 나, 단 
회  스 이를 통  입 노출 었  본 연구에 는 배출
는 이 보다 약 2 – 20 배 가량 낮았고 배출 는 이 
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달랐다. 본 연구  결과는 산업 장 같  DEHP 입노출이 
주  발생 는 경우, DEHP 입 노출평가를 여 
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